国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (8): 631-634.doi: 10.3760/cma.j.issn.1673422X.2015.08.019

• 综述 • 上一篇    下一篇

 程序性死亡配体1及其抑制剂在非小细胞肺癌中的研究进展

耿睿,潘莉,宋霞   

  1. 030013太原，山西医科大学附属肿瘤医院呼吸二病区
  • 出版日期:2015-08-08 发布日期:2015-06-29
  • 通讯作者: 宋霞，Email:songxia76@hotmail.com E-mail:songxia76@hotmail.com

Advances of programmed death ligand 1 and its inhibitor in nonsmall cell lung cancer

 GENG  Rui, PAN  Li, SONG  Xia   

  1. Second Ward of Department of Respiratory, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China
  • Online:2015-08-08 Published:2015-06-29
  • Contact: Song Xia E-mail:songxia76@hotmail.com

PDF

1575

摘要： 程序性死亡配体1（PDL1）以细胞膜型PDL1和可溶性PDL1两种形式在NSCLC中高表达，通过与其受体结合参与肿瘤免疫逃逸。目前PDL1抑制剂已进入NSCLC的Ⅰ期临床试验并反应良好，其治疗敏感性与肿瘤组织PDL1的表达状态显著相关，因而PDL1有望成为预测其药物疗效的生物学标志物。

关键词: 癌, 非小细胞肺, 免疫抑制剂, 程序性死亡配体1

Abstract: Programmed deathligand 1 (PDL1), which is highly expressed in NSCLC, can be divided into two categories: membrane PDL1 and soluble PDL1. PDL1 participates in tumor immune escape through combining with its receptor. PDL1 immune checkpoint inhibitors have entered the phase Ⅰ studies and showed a good application prospect. It is also found that the sensitivity of PDL1 immune checkpoint inhibitors is strongly associated with the expression of PDL1 in tumor. Therefore, PDL1 can be used as a biomarker to predict its curative effect.

Key words: Carcinoma, nonsmall cell lung, Immunosuppressive agents, Programmed death ligand 1